PLoS ONE (Jan 2016)

A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis.

  • Vibe Skov,
  • Mark Burton,
  • Mads Thomassen,
  • Thomas Stauffer Larsen,
  • Caroline H Riley,
  • Ann Brinch Madelung,
  • Lasse Kjær,
  • Henrik Bondo,
  • Inger Stamp,
  • Mats Ehinger,
  • Rasmus Dahl-Sørensen,
  • Nana Brochmann,
  • Karsten Nielsen,
  • Jürgen Thiele,
  • Morten K Jensen,
  • Ole Weis Bjerrum,
  • Torben A Kruse,
  • Hans Carl Hasselbalch

DOI
https://doi.org/10.1371/journal.pone.0161570
Journal volume & issue
Vol. 11, no. 8
p. e0161570

Abstract

Read online

Recent studies have shown that a large proportion of patients classified as essential thrombocythemia (ET) actually have early primary prefibrotic myelofibrosis (prePMF), which implies an inferior prognosis as compared to patients being diagnosed with so-called genuine or true ET. According to the World Health Organization (WHO) 2008 classification, bone marrow histology is a major component in the distinction between these disease entities. However, the differential diagnosis between them may be challenging and several studies have not been able to distinguish between them. Most lately, it has been argued that simple blood tests, including the leukocyte count and plasma lactate dehydrogenase (LDH) may be useful tools to separate genuine ET from prePMF, the latter disease entity more often being featured by anemia, leukocytosis and elevated LDH. Whole blood gene expression profiling was performed in 17 and 9 patients diagnosed with ET and PMF, respectively. Using elevated LDH obtained at the time of diagnosis as a marker of prePMF, a 7-gene signature was identified which correctly predicted the prePMF group with a sensitivity of 100% and a specificity of 89%. The 7 genes included MPO, CEACAM8, CRISP3, MS4A3, CEACAM6, HEMGN, and MMP8, which are genes known to be involved in inflammation, cell adhesion, differentiation and proliferation. Evaluation of bone marrow biopsies and the 7-gene signature showed a concordance rate of 71%, 79%, 62%, and 38%. Our 7-gene signature may be a useful tool to differentiate between genuine ET and prePMF but needs to be validated in a larger cohort of "ET" patients.